Genmab — December 2025
-
Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared https://pj.jiho.jp/article/254456
-
Godmorgen
-
Genmab to discontinue clinical development of acasunlimab following a portfolio review
Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscape
This decision does not impact Genmab’s full‑year 2025 financial guidance -
Genmab stopper yderligere udvikling af potentiel lungekræftkandidat https://proinvestor.com/investornyt/1398068/genmab-stopper-yderligere-udvikling-af-potentiel-lungekraeftkandidat
-
Tror snarer, at det er begyndelsen på enden. Så vi vil nok se nogle pæne tildelinger af optioner m.v., på yderst favorable vilkår. Jeg ser ingen fremtid efter bortfald af Dara pengene. Må indrømme, det har jeg ageret efter. Tak for en spændende periode ;-D
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind